Quick Answer
Acurx Pharmaceuticals, Inc. reported Operating Income of -$8.09 million for fiscal year 2025.
Acurx Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$8.09M | +42.7% |
| 2024 | -$14.12M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.03M | +28.2% | +10.6% |
| June 30, 2025 | -$2.27M | +44.9% | +19.7% |
| September 30, 2024 | -$2.83M | — | +31.4% |
| June 30, 2024 | -$4.12M | — | — |
- Acurx Pharmaceuticals, Inc. showed an increase of +42.7% in Operating Income compared to the prior fiscal year.
- Over the 2024–2025 period, Acurx Pharmaceuticals, Inc.’s operating income has grown by 42.7% (from -$14.12 million to -$8.09 million).
- The most recent figure is from Acurx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: